相似文献
1
Clinical trials in melanoma patients with brain metastases.
Pigment Cell Melanoma Res. 2015 Nov;28(6):741-3. doi: 10.1111/pcmr.12401. Epub 2015 Aug 20.
2
Treatment of melanoma brain metastases: a new paradigm.
Cancer J. 2012 Mar-Apr;18(2):208-12. doi: 10.1097/PPO.0b013e31824b2890.
3
Radiotherapy and immunotherapy: Can this combination change the prognosis of patients with melanoma brain metastases?
Cancer Treat Rev. 2016 Nov;50:1-8. doi: 10.1016/j.ctrv.2016.08.003. Epub 2016 Aug 18.
4
Enrollment Trends Among Patients with Melanoma Brain Metastasis in Active Clinical Trials.
Cancer Invest. 2024 May;42(5):400-407. doi: 10.1080/07357907.2024.2354809. Epub 2024 May 22.
5
Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases.
Neuro Oncol. 2015 Oct;17(10):1312-21. doi: 10.1093/neuonc/nov093. Epub 2015 May 25.
6
Treatment of Melanoma CNS Metastases.
Cancer Treat Res. 2016;167:263-79. doi: 10.1007/978-3-319-22539-5_11.
7
Combination therapies for treating metastatic melanoma.
Clin Adv Hematol Oncol. 2015 Apr;13(4):211-4.
8
The role of systemic therapies in the management of melanoma brain metastases.
Curr Opin Oncol. 2014 Mar;26(2):222-9. doi: 10.1097/CCO.0000000000000057.
9
Radiation necrosis of the brain in melanoma patients successfully treated with ipilimumab, three case studies.
Eur J Cancer. 2012 Nov;48(16):3045-51. doi: 10.1016/j.ejca.2012.05.016. Epub 2012 Jun 22.
10
Advances in therapy for melanoma brain metastases.
Clin Dermatol. 2013 May-Jun;31(3):264-81. doi: 10.1016/j.clindermatol.2012.08.008.
引用本文的文献
1
Outcomes of Treatment for Melanoma Brain Metastases.
J Skin Cancer. 2020 Nov 5;2020:7520924. doi: 10.1155/2020/7520924. eCollection 2020.
2
Self-Assembled, Adjuvant/Antigen-Based Nanovaccine Mediates Anti-Tumor Immune Response against Melanoma Tumor.
Polymers (Basel). 2018 Sep 25;10(10):1063. doi: 10.3390/polym10101063.
3
Comparing available criteria for measuring brain metastasis response to immunotherapy.
J Neurooncol. 2017 May;132(3):479-485. doi: 10.1007/s11060-017-2398-8. Epub 2017 Mar 8.
4
Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer.
Oncologist. 2017 Jan;22(1):70-80. doi: 10.1634/theoncologist.2016-0164. Epub 2016 Aug 17.
5
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.
Lancet Oncol. 2016 Jul;17(7):976-983. doi: 10.1016/S1470-2045(16)30053-5. Epub 2016 Jun 3.
6
Systemic Immunotherapy for the Treatment of Brain Metastases.
Front Oncol. 2016 Mar 9;6:49. doi: 10.3389/fonc.2016.00049. eCollection 2016.
本文引用的文献
1
Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.
Cancer Med. 2015 Aug;4(8):1205-13. doi: 10.1002/cam4.475. Epub 2015 May 20.
2
Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.
Eur J Cancer. 2014 Feb;50(3):611-21. doi: 10.1016/j.ejca.2013.11.002. Epub 2013 Nov 29.
3
Advances in therapy for melanoma brain metastases.
Clin Dermatol. 2013 May-Jun;31(3):264-81. doi: 10.1016/j.clindermatol.2012.08.008.
4
Brain metastases from HER2-positive breast cancer - authors' reply.
Lancet Oncol. 2013 Jan;14(1):e3-4. doi: 10.1016/S1470-2045(12)70555-7.
5
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.
Lancet Oncol. 2012 Nov;13(11):1087-95. doi: 10.1016/S1470-2045(12)70431-X. Epub 2012 Oct 8.
6
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.
Lancet Oncol. 2012 Sep;13(9):879-86. doi: 10.1016/S1470-2045(12)70324-8. Epub 2012 Aug 13.
7
Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival.
J Neurosurg. 2012 Aug;117(2):227-33. doi: 10.3171/2012.5.JNS111929. Epub 2012 Jun 15.
8
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.
Lancet. 2012 May 19;379(9829):1893-901. doi: 10.1016/S0140-6736(12)60398-5.
9
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.
Lancet Oncol. 2012 May;13(5):459-65. doi: 10.1016/S1470-2045(12)70090-6. Epub 2012 Mar 27.
10
Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutation.
J Thorac Oncol. 2012 Mar;7(3):623-5. doi: 10.1097/JTO.0b013e318241daab.
Zotero 插件